‘The silver lining’: Biotech IPOs in the time of coronavirus
The COVID-19 pandemic has upended the public markets, but every cloud has a silver lining and experts agree that, in this case, it’s the biotech industry.
“The biotech market is unique for a few factors, one of them being the long-term nature of investors who support these fields,” Jordan Saxe, head of healthcare listings at Nasdaq, told FierceBiotech. “They’re not focused on a quarter-to-quarter metric; they’re looking at an average milestone readout that is at least 12 months from the IPO.”
